Treatment of advanced breast cancer with a combination of highly agglutinative staphylococcin and vinorelbine-based chemotherapy.
Breast cancer is the most frequently diagnosed cancer among women in over 75% of countries worldwide accounting for one in four of all cancers in women. Highly agglutinative staphylococcin (HAS), a mixture of Staphylococcus aureus culture filtrates, has been used clinically as an immunomodifier in the treatment of a number of tumors for many years. The aim of present study is to evaluate the therapeutic effects and safety of treating advanced breast cancer patients with a combined therapy of HAS and vinorelbine-based chemotherapy compared to patients who receive standard chemotherapy alone.



A total of 62 patients with advanced breast cancer were divided into 2 study groups. One group received intravenous injections of HAS and vinorelbine-based chemotherapy (n=31) compared to a control group assigned to receive vinorelbine-based standard chemotherapy (n=31).



Patients with advanced breast cancer who received HAS combined therapy showed a significantly higher overall response rate (Complete Response + Partial Response) of 67.7% compared with patients who received systemic chemotherapy alone (51.6%; p < 0.05). Overall, the occurrence of adverse effects was not significantly different between study groups. HAS was able to remedy the immunosuppressing effects of standard chemotherapy in these patients.



Treatment of advanced breast cancer with of HAS - in combination with vinorelbine-based chemotherapy - was generally more effective and just as safe compared to treatment with vinorelbine-based standard chemotherapy alone.
Department of Chemotherapy, and Department of Interventional Therapy; Tumor Hospital Affiliated to Guangxi Medical University, Nanning, China. qitao_yu1@163.com.
Q-T
QT
Yu
Z-B
ZB
Meng
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001430:Bacteriocins / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000628:therapy; D005260:Female; D006801:Humans; D013211:Staphylococcus aureus; D014747:Vinblastine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077235:Vinorelbine
D001430:Bacteriocins; C017724:staphylococcin; D014747:Vinblastine; D000077235:Vinorelbine